^
    Apply
    A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) (NCT04975308)
    Phase 3
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    10/04/2021
    Primary completion :
    06/24/2024
    Completion :
    08/01/2027
    HER-2 • ER
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant • exemestane • Inluriyo (imlunestrant)
    A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer (NCT05509790)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    10/09/2022
    Primary completion :
    02/18/2024
    Completion :
    12/01/2025
    HER-2 • ER
    |
    HER-2 negative
    |
    Inluriyo (imlunestrant)
    A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) (NCT05514054)
    Phase 3
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    10/04/2022
    Primary completion :
    10/01/2027
    Completion :
    03/01/2032
    HER-2 • ER
    |
    HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)
    A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) (NCT04188548)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    01/22/2025
    Initiation :
    12/10/2019
    Primary completion :
    06/29/2020
    Completion :
    12/01/2027
    ER
    |
    HER-2 negative • EGFR positive
    |
    Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)
    A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) (NCT05307705)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    10/26/2024
    Initiation :
    05/11/2022
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    HER-2 • ER • PIK3CA
    |
    HER-2 negative • PIK3CA mutation
    |
    paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant) • LOXO-783
    A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2) (NCT04647487)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    03/31/2023
    Initiation :
    04/21/2021
    Primary completion :
    11/11/2022
    Completion :
    11/11/2022
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Inluriyo (imlunestrant)